It has been shown that the majority of glioma patients do not respond to blockade of the usual immune checkpoint pathways, such as programmed death receptor-1 (PD1), its ligand (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) [6,7,8]. Here, CTLA4 is linked to glioma.